Musculoskeletal Manifestations
- Sjogren syndrome is a chronic AUTOIMMUNE EXOCRINOPATHY in which lymphocytic infiltration of the LACRIMAL and SALIVARY glands produces SICCA - keratoconjunctivitis sicca (dry, gritty eyes) and xerostomia (dry mouth) - with systemic extraglandular involvement; it is PRIMARY when it occurs alone and SECONDARY when it accompanies another connective-tissue disease (rheumatoid arthritis, SLE, systemic sclerosis).
- MUSCULOSKELETAL involvement is among the most common extraglandular features: ARTHRALGIA is very frequent, and there is often a NON-EROSIVE inflammatory ARTHRITIS in a symmetric small-joint (RA-like) distribution that, unlike rheumatoid arthritis, usually does NOT cause erosive joint destruction - recognising this helps distinguish it from RA at presentation.
- MYALGIA is common, and an inflammatory MYOPATHY can occur (overlap with the inflammatory myopathies); a fibromyalgia-type widespread pain and fatigue frequently coexist and contribute to the musculoskeletal symptom burden.
- The SEROLOGY is characteristic - ANTI-Ro (SSA) and ANTI-La (SSB) antibodies, positive ANA and rheumatoid factor, and a polyclonal raised IgG - and these antibodies (especially anti-Ro) are important beyond diagnosis (e.g. neonatal lupus/congenital heart block in pregnancy); classification uses validated criteria incorporating serology and gland involvement.
- A clinically important feature is the increased risk of B-cell (MALT) LYMPHOMA in Sjogren syndrome, so persistent salivary-gland swelling, lymphadenopathy or new systemic features warrant vigilance - this is the most serious complication and a recurring exam point.
- MANAGEMENT is directed at SYMPTOMS and the SYSTEMIC disease: symptomatic care of the sicca (artificial tears/saliva), and for the inflammatory MSK disease NSAIDs, HYDROXYCHLOROQUINE, and other DMARDs/immunosuppression for significant systemic involvement; the ORTHOPAEDIC relevance is mainly to recognise Sjogren syndrome as the systemic disease behind a seropositive, usually non-erosive arthritis (and to coordinate any joint care, including the dry-eye/mouth and perioperative considerations, with rheumatology).
- “Sjogren = autoimmune exocrinopathy (sicca: dry eyes + mouth) + anti-Ro (SSA)/anti-La (SSB). PRIMARY (alone) vs SECONDARY (with RA/SLE/other CTD).
- “MSK: arthralgia is VERY common; arthritis is usually NON-EROSIVE (RA-like distribution but not destructive). Myalgia/inflammatory myopathy can occur.
- “Key complication = increased B-cell (MALT) LYMPHOMA risk - be alert to persistent gland swelling/lymphadenopathy. Treat symptoms + systemic disease (hydroxychloroquine/DMARDs).
Sicca (dry eyes/mouth) + arthralgia and a usually non-erosive RA-like arthritis, with anti-Ro (SSA)/anti-La (SSB) antibodies. Primary (alone) or secondary (with RA/SLE/CTD).
Increased risk of B-cell (MALT) lymphoma - persistent salivary-gland swelling or lymphadenopathy needs vigilance/investigation.
What It Is & Its Musculoskeletal Footprint
Sjogren syndrome is a chronic autoimmune exocrinopathy - lymphocytic infiltration of the lacrimal and salivary glands causing sicca (dry eyes and mouth) - that is primary (alone) or secondary (with another connective-tissue disease). Musculoskeletal involvement is among the commonest extraglandular features: arthralgia is very frequent and there is often a non-erosive inflammatory arthritis in an RA-like symmetric small-joint distribution that, unlike rheumatoid arthritis, usually does not destroy the joints; myalgia and an inflammatory myopathy can also occur. The serology - anti-Ro (SSA)/anti-La (SSB), ANA, rheumatoid factor and a raised IgG - is characteristic, and there is an increased risk of B-cell (MALT) lymphoma.
| Feature | Sjogren syndrome | Rheumatoid arthritis |
|---|---|---|
| Joint damage | Usually NON-erosive | Erosive, destructive |
| Distribution | Symmetric small-joint (RA-like) | Symmetric small-joint |
| Defining serology | Anti-Ro (SSA)/anti-La (SSB) | Anti-CCP / rheumatoid factor |
| Sicca | Prominent (dry eyes/mouth) | Can be secondary Sjogren |
| Key risk | B-cell (MALT) lymphoma | Erosive joint destruction |
Management
- Sicca: artificial tears/saliva, eye/mouth care, secretagogues - symptomatic.
- Inflammatory MSK disease: NSAIDs, hydroxychloroquine, and other DMARDs/immunosuppression for significant systemic involvement.
- Vigilance for lymphoma: investigate persistent salivary-gland swelling, lymphadenopathy or new systemic features.
- Orthopaedic relevance: recognise Sjogren behind a seropositive, usually non-erosive arthritis; coordinate joint care (and dry-eye/mouth and perioperative considerations) with rheumatology.
The two practical lessons in the musculoskeletal aspects of Sjogren syndrome are diagnostic. First, although the arthralgia and arthritis can look like rheumatoid arthritis in distribution, the Sjogren arthritis is usually non-erosive and is defined by anti-Ro/anti-La antibodies (rather than anti-CCP), and the prominent sicca points to the diagnosis - so a seropositive, non-erosive symmetric arthritis with dry eyes and mouth should be recognised as Sjogren (primary or secondary) rather than simply managed as rheumatoid disease. Second, Sjogren syndrome carries a well-recognised increased risk of B-cell (MALT) lymphoma, so persistent salivary-gland enlargement, new lymphadenopathy, or new systemic features should not be dismissed but investigated. For the orthopaedic surgeon the disease is mostly a systemic context to recognise behind joint symptoms, to be managed with the rheumatology team, with attention to the sicca and to perioperative immunosuppression.
Evidence & Key Studies
Rheumatic-disease (incl. Sjogren) arthritis of the temporomandibular joint - rehabilitative pain relief
- Rheumatic diseases - a heterogeneous group affecting the musculoskeletal system including the joints - encompass Sjogren syndrome among the conditions that can cause inflammatory joint involvement (here, of the temporomandibular joint).
- Conservative rehabilitative approaches (e.g. intra-articular corticosteroid injection, low-level laser therapy) may relieve pain in rheumatic-disease-related arthritis, though the evidence quality is limited.
- This supports a symptomatic, conservative-first approach to inflammatory joint involvement in rheumatic diseases such as Sjogren syndrome.
According to PubMed, the inclusion of Sjogren syndrome among rheumatic diseases that cause inflammatory joint involvement, and the role of conservative rehabilitative measures for the resulting joint pain, are supported by the cited Aiello systematic review. The defining features of Sjogren syndrome (autoimmune exocrinopathy with sicca, anti-Ro/anti-La serology), its very common arthralgia and usually non-erosive arthritis, the primary-versus- secondary distinction, and the increased B-cell (MALT) lymphoma risk are standard, well-established teaching. (See also our Rheumatoid Arthritis, Systemic Lupus Erythematosus and Connective-Tissue Disease topics.)
Clinical Decision Scenarios
Practise clinical reasoning and management decisions out loud
“A patient with dry eyes and dry mouth has a symmetric small-joint arthralgia. How do you approach this, and how does it differ from rheumatoid arthritis?”
Mnemonics & Memory Aids
DRYNESS
Hook:DRYNESS: Dry eyes/mouth, Ro/La antibodies, Yet non-erosive, Non-erosive arthritis, Either primary/secondary, Swelling -> Suspect lymphoma, Symptomatic+Systemic Rx.
What it is
- Autoimmune exocrinopathy: sicca (dry eyes/mouth) from lymphocytic gland infiltration
- Primary (alone) or secondary (with RA/SLE/other CTD)
- Serology: anti-Ro (SSA)/anti-La (SSB), ANA, RF, raised IgG
Musculoskeletal
- Arthralgia very common; usually NON-EROSIVE inflammatory arthritis (RA-like distribution)
- Myalgia common; inflammatory myopathy (overlap) can occur
- Distinguish from RA: non-erosive, anti-Ro/La (not anti-CCP)
Key risk
- Increased B-cell (MALT) lymphoma risk
- Investigate persistent salivary-gland swelling/lymphadenopathy
- Most serious complication
Management
- Sicca: artificial tears/saliva, secretagogues (symptomatic)
- Inflammatory MSK: NSAIDs, hydroxychloroquine, DMARDs/immunosuppression
- Coordinate joint care + perioperative considerations with rheumatology